02:41:23 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-04-19 Ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-19 Ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-22 Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar nya cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.
2022-03-11 08:13:00
Oslo, 11 March 2022. Lytix Biopharma - a clinical-stage company with an in situ
vaccination technology platform - is pleased to announce that Dr Øystein Rekdal,
CEO in Lytix Biopharma, today will deliver an oral presentation at the 6th
Annual Next Gen Immuno-Oncology Congress, which is taking place in London, UK.

Rekdal will discuss the major challenges represented by tumor heterogeneity and
how oncolytic molecules can address this challenge by inducing a strong and
broad activation of the immune system.


"Our in situ vaccination technology platform delivers molecules with the
potential to solve one of the major hurdles in cancer treatment. We are grateful
for being invited to this annual next gen immuno-oncology conference and to
present our proposed solution to the problem of genetic heterogeneity in cancer
immunotherapy", says Dr. Øystein Rekdal.


Title: Addressing Tumor Heterogeneity with Oncolytic Molecules - an unsolved
issue in Cancer
Date and time: Friday 11 March 2022 at 14.30-15.00 EST

For more information, please contact:
Øystein Rekdal, CEO: +47 975 73 358
Gjest Breistein, CFO: +47 952 60 512
Ole Peter Nordby, Head of IR: +47 412 87 179

About the Congress
The 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress will address
the challenges and future directions in immuno-oncology research. The congress
aims to bring academicians, researchers and scientists from research institutes
pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the
latest updates in development of ADC's, Bispecific Antibodies, Cellular Therapy
and Immune Checkpoint Inhibitors. This congress will also focus on various
combination strategies, pre-clinical and translational immune-oncology
developments, updates in cellular and viral therapies, vaccines development and
personalized immunotherapy. Keynote presentations, Brainstorming Panel
Discussions and Case studies will give the stakeholders an opportunity to
discuss and understand the issues faced and come up with solutions.
https://events.marketsandmarkets.com/6th-annual-marketsandmarkets-next-gen-immun
o-oncology-congress-uk/

Lytix Biopharma in brief
Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company
developing novel cancer immunotherapies, an area within cancer therapy that is
aimed at activating the patient's immune system to fight cancer. The Company's
technology is based on pioneering research in "host defense peptides" - nature's
first line of defense towards foreign pathogens. Lytix Biopharma's lead product,
LTX-315, is a first-in-class oncolytic molecule representing a new and superior
in situ therapeutic vaccination principle to boost anti-cancer immunity, with
the potential to be the ideal combination partner with other types of
immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens. This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.